CHF and arrhythmias:

Indications for: VERQUVO

To reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for HF or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction <45%.

Adult Dosage:

Tabs may be crushed and mixed with water, if unable to swallow whole. Take with food. Initially 2.5mg once daily; then double the dose approx. every 2 weeks. Target dose: 10mg once daily as tolerated.

Children Dosage:

Not established.

VERQUVO Contraindications:

Pregnancy. Concomitant other sGC stimulators.

Boxed Warning:

Embryo-fetal toxicity.

VERQUVO Warnings/Precautions:

Embryo-fetal toxicity. Exclude pregnancy status prior to initiation. Advise females of reproductive potential to use effective contraception during and for at least 1 month after the last dose. Nursing mothers: not recommended. Severe hepatic impairment or eGFR <15mL/min/1.73m2 at treatment initiation or on dialysis: not studied.

VERQUVO Classification:

Soluble guanylate cyclase (sGC) stimulator.

VERQUVO Interactions:

See Contraindications. Concomitant PDE-5 inhibitors: not recommended.

Adverse Reactions:

Hypotension, anemia.

Generic Drug Availability:


How Supplied:

Tabs 2.5mg, 5mg—14, 30, 100 (10×10 blisters); 10mg—30, 90, 100 (10×10 blisters)